GlassScriptPhysician profile
Jeffrey D Markey
NPI 1255628848
$1,973.41
in general payments reported to CMS, 2019-2025
27 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $222 · 2021: $482 · 2022: $371 · 2023: $357 · 2024: $107 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $368.34 | 2019-2024 | Scopis Ent, Core |
| Intersect Ent, INC. | $334.83 | 2021-2022 | |
| Glaxosmithkline, LLC. | $211.27 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $207.30 | 2022-2025 | |
| Musculoskeletal Transplant Foundation INC. | $148.59 | 2023 | |
| Depuy Synthes Sales INC. | $106.99 | 2019-2020 | |
| Acclarent, INC | $85.31 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $61.57 | 2019-2025 | |
| Hologic Sales and Service, LLC | $48.85 | 2023-2024 | Coolseal Generator |
| Optinose US, INC. | $45.24 | 2020-2023 | |
| Innovation Technologies INC | $37.02 | 2023 | Irrisept |
| Kowa Pharmaceuticals America, INC. | $31.95 | 2022 | |
| Olympus America INC. | $29.38 | 2022 | |
| Sientra, INC. | $27.74 | 2022 | |
| Integra Lifesciences Corporation | $26.57 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.05 | 2022 | |
| Grifols USA, LLC | $21.96 | 2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $18.38 | 2023 | Dupixent |
| Smith+Nephew, INC. | $18.23 | 2021 | |
| Merck Sharp & Dohme LLC | $17.36 | 2023 | |
| Abbvie INC. | $17.14 | 2025 | |
| Deroyal Industries, INC. | $16.88 | 2023 | Prospera Pro Negative Pressure Wound Therapy Units |
| Baudax Bio INC. | $15.14 | 2020 | |
| Melinta Therapeutics, LLC | $14.13 | 2025 | Rezzayo, Kimyrsa |
| Horizon Therapeutics Plc | $13.70 | 2019 | |
| Galderma Laboratories, L.P. | $13.70 | 2019 | |
| Kaleo, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Markey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.